5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorderNot yet recruitingPhase 32026-10-08NCT07578649
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinomaRecruitingPhase 2 / Phase 32026-10-08NCT07226999
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 1 / Phase 22026-09-09NCT06966453
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderRecruitingPhase 32026-05-06NCT07062965
Breast Cancer Index (BCI) RegistryNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingNot stated2024-09-19NCT04875351